Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Smoldering Multiple Myeloma 3Pancreatic Neoplasms 2Multiple Myeloma 2Melanoma 2Glioma 2Central Nervous System Neoplasms 2Brain Neoplasms 2Arthritis, Rheumatoid 2Triple Negative Breast Neoplasms 1Sarcoma 1Prostatic Neoplasms 1PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Myasthenia Gravis 1Multiple Endocrine Neoplasia 1Lung Neoplasms 1Hematologic Neoplasms 1Gliosarcoma 1Glioblastoma 1Colorectal Neoplasms 1Breast Neoplasms 1Breast Diseases 1Astrocytoma 1Acute Graft Versus Host Disease 1

Interventions

Anastrozole 8exemestane 7Trastuzumab 7Letrozole 7palbociclib 6Docetaxel 6abemaciclib 5Fulvestrant 5ribociclib 4pyrotinib 4entinostat 4Cyclophosphamide 4Tamoxifen 3Doxorubicin 3pertuzumab 2Sodium Chloride 2Paclitaxel 2Lapatinib 2Gonadotropin-Releasing Hormone 2Exercise 2Everolimus 2Epirubicin 2Drug Evaluation 2Capecitabine 2Botulinum Toxins, Type A 2Blood Specimen Collection 2Aromatase Inhibitors 2AZD9833 2tucatinib 1trastuzumab deruxtecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Diseases × Leflunomide × Clear all
NCT03709446 2026-03-19

Leflunomide in Previously Treated Metastatic Triple Negative Cancers

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
17 enrolled
Breast

Breast Diseases, Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡